The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study
Open accessAbstract
Background Plasma tau phosphorylated at threonine 217 (p-tau217) and plasma tau phosphorylated at threonine 181 (p-tau181) are associated with Alzheimer's disease tau pathology. We compared the diagnostic value of both biomarkers in cognitively unimpaired participants and patients with a clinical diagnosis of mild cognitive impairment, Alzheimer's disease syndromes, or frontotemporal lobar degeneration (FTLD) syndromes.Methods In this retrospective multicohort diagnostic performance study, we analysed plasma samples, obtained from patients aged 18-99 years old who had been diagnosed with Alzheimer's disease syndromes (Alzheimer's disease dementia, logopenic variant primary progressive aphasia, or posterior cortical atrophy), FTLD syndromes (corticobasal syndrome, progressive supranuclear palsy, behavioural variant frontotemporal dementia, non-fluent variant primary progressive aphasia, or semantic variant primary progressive aphasia), or mild cognitive impairment; the participants were from the University of California San Francisco (UCSF) Memory and Aging Center, San Francisco, CA, USA, and the Advancing Research and Treatment for Frontotemporal Lobar Degeneration Consortium (ARTFL; 17 sites in the USA and two in Canada). Participants from both cohorts were carefully characterised, including assessments of CSF p-tau181, amyloid-PET or tau-PET (or both), and clinical and cognitive evaluations. Plasma p-tau181 and p-tau217 were measured using electrochemiluminescence-based assays, which differed only in the biotinylated antibody epitope specificity. Receiver operating characteristic analyses were used to determine diagnostic accuracy of both plasma markers using clinical diagnosis, neuropathological findings, and amyloid-PET and tau-PET measures as gold standards. Difference between two area under the curve (AUC) analyses were tested with the Delong test.Findings Data were collected from 593 participants (443 from UCSF and 150 from ARTFL, mean age 64 years [SD 13], 294 [50%] women) between July 1 and Nov 30, 2020. Plasma p-tau217 and p-tau181 were correlated (r=0·90, p<0·0001). Both p-tau217 and p-tau181 concentrations were increased in people with Alzheimer's disease syndromes (n=75, mean age 65 years [SD 10]) relative to cognitively unimpaired controls (n=118, mean age 61 years [SD 18]; AUC=0·98 [95% CI 0·95-1·00] for p-tau217, AUC=0·97 [0·94-0·99] for p-tau181; p diff=0·31) and in pathology-confirmed Alzheimer's disease (n=15, mean age 73 years [SD 12]) versus pathologically confirmed FTLD (n=68, mean age 67 years [SD 8]; AUC=0·96 [0·92-1·00] for p-tau217, AUC=0·91 [0·82-1·00] for p-tau181; p diff=0·22). P-tau217 outperformed p-tau181 in differentiating patients with Alzheimer's disease syndromes (n=75) from those with FTLD syndromes (n=274, mean age 67 years [SD 9]; AUC=0·93 [0·91-0·96] for p-tau217, AUC=0·91 [0·88-0·94] for p-tau181; p diff=0·01). P-tau217 was a stronger indicator of amyloid-PET positivity (n=146, AUC=0·91 [0·88-0·94]) than was p-tau181 (n=214, AUC=0·89 [0·86-0·93]; p diff=0·049). Tau-PET binding in the temporal cortex was more strongly associated with p-tau217 than p-tau181 (r=0·80 vs r=0·72; p diff<0·0001, n=230).Interpretation Both p-tau217 and p-tau181 had excellent diagnostic performance for differentiating patients with Alzheimer's disease syndromes from other neurodegenerative disorders. There was some evidence in favour of p-tau217 compared with p-tau181 for differential diagnosis of Alzheimer's disease syndromes versus FTLD syndromes, as an indication of amyloid-PET-positivity, and for stronger correlations with tau-PET signal. Pending replication in independent, diverse, and older cohorts, plasma p-tau217 and p-tau181 could be useful screening tools to identify individuals with underlying amyloid and Alzheimer's disease tau pathology.Funding US National Institutes of Health, State of California Department of Health Services, Rainwater Charitable Foundation, Michael J Fox foundation, Association for Frontotemporal Degeneration, Alzheimer's Association.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, plasma p‐tau217 often shows a superior association with temporal lobe tau load compared to other plasma biomarkers (including other p‐tau species), 13 , 25 , 36”
From Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several recent studies have reported that plasma biomarkers have excellent diagnostic accuracy for AD, with sensitivity or specificity often exceeding 90% (refs. 4–10).”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although total tau and amyloid β concentrations are not sensitive or specific for any of the frontotemporal lobar degeneration proteinopathies, elevated phosphorylated tau concentrations in either CSF or plasma suggest that underlying Alzheimer's disease pathology is likely to be the cause of the frontotemporal dementia clinical syndrome.49,55,56”
From Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations (2022) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Notably, p-tau217 exhibits larger-fold changes compared with p-tau181 and p-tau231,10 often achieving high discrimination, with areas under the curve (AUC) exceeding 90%.19,23”
From Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology (2024) · cites this paper as [23]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although total tau and amyloid β concentrations are not sensitive or specific for any of the frontotemporal lobar degeneration proteinopathies, elevated phosphorylated tau concentrations in either CSF or plasma suggest that underlying Alzheimer's disease pathology is likely to be the cause of the frontotemporal dementia clinical syndrome.49,55,56”
From Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations (2022) · cites this paper as [56]
Experimental — accuracy not yet measured
In the citing paper
“Like NfL (neurofilament light chain), plasma tau has emerged as a marker of neuronal distress. It appears in several different neurodegenerative diseases, including importantly even preclinical AD patients (76–85).”
From All the Tau We Cannot See (2023) · cites this paper as [85]
In the citing paper
“It appears to be more specific for AD pathology, at least compared to frontotemporal dementia and chronic traumatic encephalopathy (85, 91, 92), but it is increased in prion disease (83).”
From All the Tau We Cannot See (2023) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Self-citationDiagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Self-citationMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
Appelhof, B., Bakker, C., den IJssel, J. C. L. V. D., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,774
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., et al. (2017) · Movement Disorders · doi:10.1002/mds.26987 · Cited by 2,434
Self-citation
Cited by
Sorted by citations
Items 401–500 of 614
Wu, L., Su, J., Li, G., Zhuang, M., Sun, H., & Zhang, J. (2025) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaf058 · Cited by 6
Barba, L., Bellomo, G., Alcolea, D. A., Wojdała, A. L., Gaetani, L., Fortea, J., Abu‐Rumeileh, S., Lleó, A., Parnetti, L., Belbin, O., et al. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2025-336189 · Cited by 5
Bridging prion biology and Alzheimer’s disease: from pathogenic seeds to precision therapeutics
Wang, W., Feng, Z., Shu, L., Hu, Y., Chen, Y., Zhang, B., & Huang, H. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1660151 · Cited by 3
Top 100 most-cited articles on tau protein: a bibliometric analysis and evidence mapping
Chen, Z., Shan, G., Wang, X., Zuo, Y., Song, X., Ma, Y., Zhao, X., & Jin, Y. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1345225 · Cited by 3
The Dementia UK Ecosystem: a call to action
Lalli, G., Rossor, M. N., Rowe, J. B., & Strooper, B. D. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00246-5 · Cited by 3
Advances in Alzheimer's Disease Biomarkers
Li, K., Gao, Y., Liu, M., & Chen, Y. (2024) · Current Alzheimer Research · doi:10.2174/0115672050366767241223050957 · Cited by 3
Sato, K., Niimi, Y., Ihara, R., Iwata, A., Suzuki, K., & Iwatsubo, T. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70065 · Cited by 2
A novel pThr217 tau monoclonal antibody reveals neuropathological heterogeneity in tauopathies
Paterno, G., Bell, B. M., Gorion, K.-M. M., Quintin, S. S., Prokop, S., & Giasson, B. I. (2025) · Scientific Reports · doi:10.1038/s41598-025-04291-y · Cited by 2
Early cerebrospinal fluid elevations of pTau-217 in severe traumatic brain injury subjects
Yadikar, H., Kobeissy, F. H., Robertson, C. S., Tsetsou, S., Williamson, J. B., Lamb, D. G., Wagner, A. K., Kibaugh, T., Kao, S.-H., Kou, Z., et al. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1632679 · Cited by 3
Chen, Y., Li, M., Li, J., Liang, P., Cheng, Z., Wang, N., Zhang, X., Wang, Y., Zhang, N., Che, Y., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70710 · Cited by 3
Hellquist, E., Janelidze, S., Weidung, B., Franzon, K., Giedraitis, V., Ingelsson, M., Bali, D., Veličkaitė, V., Zetterberg, H., Hansson, O., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251390387 · Cited by 2
Self-citationShim, S., Cho, H., Lee, J. H., Cho, W. W., Kim, J., Lee, S.-M., Lee, S.-M., & Shin, D. (2025) · Analytica Chimica Acta · doi:10.1016/j.aca.2025.344851 · Cited by 2
Cody, K. A., Langhough, R. E., Janelidze, S., Jonaitis, E. M., Wilson, R. E., Christian, B. T., Asthana, S., Johnson, S. C., Zetterberg, H., Hansson, O., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf449 · Cited by 4
Self-citationXi, J., He, K., Hou, L., Smets, B., Miller, S., Saad, Z. S., Whelan, C. D., Ruiz, A., Puerta, R., Cano, A. C., et al. (2026) · npj Dementia · doi:10.1038/s44400-025-00053-9 · Cited by 4
Zhang, S., Jiao, B., Zeng, Y., Sun, Q., Chen, X., Zhang, W., Ouyang, Z., Xiao, Q., Zhou, L., Li, Y., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106127 · Cited by 2
Cánovas, R., Fowler, C. J., Feizpour, A., Doré, V., Bourgeat, P., Saad, Z. S., Triana‐Baltzer, G., Kolb, H. C., Vandijck, M. L. J., Kollmorgen, G., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71145 · Cited by 3
Self-citationSin, M., Allman, R. M., Lin, Y., Choupani, F., Ahmed, A., & Faselis, C. J. (2026) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2026.100129 · Cited by 2
Zhang, Y., An, Y., Yang, M., Huang, Y., Yu, S., Xu, X., & Yang, C. J. (2026) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2026.139727 · Cited by 3
Tatar, A.-S., Colniță, A., Brezeștean, I.-A., & Boca, S. (2026) · Biophysical Reviews · doi:10.1007/s12551-026-01428-9 · Cited by 2
Tau pathology in epilepsy: emerging mechanisms and translational opportunities
Sen, A., Tai, X. Y., Galanopoulou, A. S., Thom, M., Aronica, E., Vivash, L. E., Hardmeier, M., Amos, A., Rüegg, S. J., Koepp, M. J., et al. (2026) · Brain · doi:10.1093/brain/awag108 · Cited by 2
Zeng, Y., Du, H., Yang, J., Guo, C., Yuan, Y., & Zhou, J. (2026) · Talanta · doi:10.1016/j.talanta.2026.129816 · Cited by 2
He, Y., 杜雨柔, Liu, D., Che, P., Wang, Y., Li, J., Wang, C., & Zhang, N. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04043-0 · Cited by 2
Zafari, R., Kamroo, A., Taherkhani, T., Nabizdeh, F., & Aarabi, M. H. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.05.010 · Cited by 3
Chai, L., Zhan, Y., Huang, Y., Tian, M., Zhao, G., Ni, J., Xiong, X., Huang, J., & Lin, B. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02104-6 · Cited by 2
López‐Martos, D., Cacciaglia, R., Suárez‐Calvet, M., Salvadó, G., Shekari, M., González‐Escalante, A., Milà‐Alomà, M., Brugulat‐Serrat, A., Minguillón, C., Tonietto, M., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100612 · Cited by 2
Self-citationPerformance of Alzheimer Disease Plasma Biomarkers in Patients With Prion Diseases
Coysh, T., Laban, R., Veleva, E., Heslegrave, A., Darwent, L., Holm-Mercer, L., Mok, T. H., Hart, M., Lunn, M. P., Keshavan, A., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000214712 · Cited by 2
Self-citationSodium selenate as a therapeutic for tauopathies: A hypothesis paper
Dilcher, R., Malpas, C. B., Walterfang, M., Velakoulis, D., O'Brien, T. J., & Vivash, L. E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.915460 · Cited by 2
Jin, M., Shi, R., Gao, D., Wang, B., Li, N., Li, X., Attila Gabor, S. I. K., Liu, K., & Zhang, X. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14407 · Cited by 3
CAPS: a simple clinical tool for β-amyloid positivity prediction in clinical Alzheimer syndrome
Lahiri, D., Lima, B. S., Roncero, C., Verhoeff, N. P. L. G., Freedman, M., Al‐Shamaa, S., & Chertkow, H. M. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1422681 · Cited by 2
Roveta, F., Rubino, E., Marcinnò, A., Grassini, A., Piella, E. M., Ferrandes, F., Bonino, L., Giaracuni, G., Boschi, S., Gioiello, G., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241313145 · Cited by 2
Developing non-invasive molecular markers for early risk assessment of Alzheimer's disease
Sur, T. K., Mondal, T., Noreen, Z., Johnson, J., Nunlee‐Bland, G., Loffredo, C. A., Korba, B. E., Chandra, V., Jana, S. S., Kwabi‐Addo, B., et al. (2025) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2025.100120 · Cited by 3
Singh, R. K., Bekena, S., Damera, N., Zhu, Y., Trani, J., & Babulal, G. M. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251365219 · Cited by 4
Alsaadi, T. M., Almadani, A., Alrukn, S., Hassan, A., Sarathchandran, P., Shatila, A. O., Szólics, M., Benito, D., İnce, S., & Krieger, D. W. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00833-8 · Cited by 2
Blood biomarkers in MCI conversion to Alzheimer’s disease: a systematic review and meta-analysis
Li, H., Wang, J., Dong, Y., Li, J., Xiao, J.-W., Ren, R., Li, C., & Wang, G. (2023) · Human Brain · doi:10.37819/hb.2.1758 · Cited by 1
Barthélemy, N. R., Saef, B. A., Li, Y., Gordon, B. A., He, Y., Horie, K., Stomrud, E., Salvadó, G., Janelidze, S., Sato, C., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2175929/v1 · Cited by 2
Self-citationMammel, A., Hsiung, G. R., Mousavi, A., Hallett, K., Mackenzie, I. R., Hirsch‐Reinshagen, V., Biehl, D., Gill, P. S., Encarnacion, M. J., & Frykman, H. (2024) · medRxiv · doi:10.1101/2024.07.27.24310872 · Cited by 2
Anastasi, F., Fernández‐Lebrero, A., Ashton, N. J., Ortiz-Romero, P. L., Torres‐Torronteras, J., González‐Escalante, A., Milà‐Alomà, M., Contador, J., García‐Escobar, G., Manero-Borràs, R. M., et al. (2024) · medRxiv · doi:10.1101/2024.10.26.24316176 · Cited by 2
Self-citationVrillon, A., Spina, S., Mejía‐Perez, J. A., LaMore, T., Yballa, C., Soleimani‐Meigooni, D. N., Blazhenets, G., Boxer, A. L., Rojas, J. C., Lago, A. L., et al. (2025) · medRxiv · doi:10.1101/2025.05.14.25326954 · Cited by 2
Self-citationTan, Y. J., Mohammadi, R., Saffari, S. E., Tan, N. I., Lim, L. S., Low, S. H., Tan, L. C., Chiew, H. J., Ng, K. P., Hameed, S., et al. (2025) · medRxiv · doi:10.1101/2025.05.22.25328192 · Cited by 2
Suresh, S., Maffei, L., Bauermeister, S., & Raymont, V. (2025) · medRxiv · doi:10.1101/2025.07.06.25330840 · Cited by 2
Faul, J. D., Crimmins, E. M., Kim, J. K., Thyagarajan, B., King, J. W., Weir, D. R., & Langa, K. M. (2026) · medRxiv · doi:10.64898/2026.01.07.26343604 · Cited by 2
Distinct mechanistic pathways of early tauopathy revealed by MAPT mutationsPreprint
Foiani, M. S., Nirujogi, R., Watamura, N., Bez, S., Tsefou, E., Santambrogio, A., Patel, S., Hannah, D., Goulbourne, C. N., Fatima, N., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.14.705716 · Cited by 2
Self-citationFei, Z., Pei, R., Pan, B., Ye, S., Zhang, R., Ma, L., Wang, Z., Li, C., Du, X., & Cao, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065549 · Cited by 1
Current Treatment Approaches for Alzheimer’s Disease and Possible Drug Targets
Ranjan, A., Shukla, S., & Singh, S. (2024) · Current Drug Therapy · doi:10.2174/0115748855307998240529063710 · Cited by 1
Xie, Y., Meng, X. W., Li, T., Zhang, H., Zheng, Y., Kim, S.-Y., Zhang, C., Yu, X., & Wang, H. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70064 · Cited by 1
Tau Pathology in Alzheimer's Disease: Bridging Molecular Mechanisms and Targeted Therapies
Dahiya, M., Yadav, M., Kumar, A., & Goyal, C. (2025) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273376581250626003322 · Cited by 2
Associations of Plasma p‐tau181 With Age, Adjusted for Kidney Function and Sociodemographic Factors
Hazan, J., Liu, K. Y., Zetterberg, H., Fox, N. C., Howard, R. J., & with, A. D. N. I. (2025) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.70138 · Cited by 2
Self-citationHuang, X., Xu, Z., Fu, F., Song, J., Zeng, J., Huang, S., & Yue, F. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110849 · Cited by 1
Wang, L., Xu, H., Simons, R. L., Beach, S. R. H., Lei, M., Ong, M. L., Philibert, R. A., Mielke, M. M., Sun, Y., Lu, Y., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213976 · Cited by 2
Diffusion Alterations at the Gray Matter/White Matter Boundary in Traumatic Encephalopathy Syndrome
Wiegand, T. L. T., Pankatz, L., Arciniega, H., Jung, L., Tuz‐Zahra, F., Sylvain Bouix, A., Lubeck, H., Rojczyk, P., Schuhmacher, L. S., Buring, J. E., et al. (2025) · Journal of Neurotrauma · doi:10.1177/08977151251393966 · Cited by 1
Self-citationTLRs and NLRs modulate oral microbiome involvement in Alzheimer’s disease
Motevalli, H., Mehrani, A., Zolfaghari, K., Khodaee, P., Yazdanpanah, N., Saleki, K., & Rezaei, N. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01771-y · Cited by 1
Blood-based biomarkers and early diagnosis of Alzheimer’s disease
Cui, Z., Li, G., Wei, S., Cheng, Q., Yu, Q., Zong, S., Zhang, P., Chen, H., Yu, S., Wu, S., et al. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00759 · Cited by 1
Ganesan, V. K. (2026) · Current Research in Translational Medicine · doi:10.1016/j.retram.2026.103568 · Cited by 1
Zamani, J., Vahid, A., Wilson, E. N., Hosseini, S. M. H., & Initiative, T. F. L. D. N. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71265 · Cited by 1
Li, S., Wei, S., Wang, L., Yu, T., Wang, H., Yang, S. B., Cao, W., & Zhang, X. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151452 · Cited by 1
Rissanen, J.-A., Kärkkäinen, S., Katisko, K., Vanninen, A., Luikku, A. J., Rauramaa, T. H., Musialowicz, T., Kokki, M., Julkunen, V., Portaankorva, A. M., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261431800 · Cited by 1
James, L. M., Stratigopoulos, G., Leuthold, A. C., & Georgopoulos, A. P. (2026) · Scientific Reports · doi:10.1038/s41598-026-44894-7 · Cited by 1
Zhang, R., Dong, X., Pei, G., & Huang, S. (2026) · Neuroscience Bulletin · doi:10.1007/s12264-026-01615-4 · Cited by 1
Predictive Ability of Plasma p‐tau217 for β‐Amyloid Status: A Prospective Multicenter Study
Massons, M., Guillén, N., Sarto, J., Falgàs, N., Borrego‐Écija, S., Esteller, D., Castellvı́, M., Tort‐Merino, A., Pérez‐Millan, A., Antonell, A., et al. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70387 · Cited by 1
Chou, P., Chien, C., Huang, L., & Yang, Y. (2026) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2026.2658530 · Cited by 1
Hirota, Y., Yamamoto, J., Takatori, S., Sakakibara, Y., Takei, K., 佐治多美子, Sekiya, M., Tomita, T., & Iijima, K. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00032-1 · Cited by 1
Prognostic Determinants of Presentation and Outcome in Anti-IgLON5 Disease
Sabater, L., Guasp, M., García, R. R., Rondán, L. N., Querol, L., Martín-Aguilar, L., Llarch, P., Balasa, M., Lladó, A., Painous, C., et al. (2026) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200600 · Cited by 1
Plasma Amyloid Beta and Tau Associations with Cerebral Amyloid Angiopathy Presence and Severity
Bax, F., Liu, L., van Harten, T. W., Gökçal, E., Horn, M. J., Warren, A., Saba, A., Shirzadi, Z., DiPucchio, Z. Y., Schwab, K. M., et al. (2026) · Annals of Neurology · doi:10.1002/ana.78264 · Cited by 1
Chen, J. K., Liang, Y., Xu, P., Kong, C., Zhang, Y. Y., 周如洋, Wu, O., Jiang, Z., Zhao, H., Song, M., et al. (2026) · Analytica Chimica Acta · doi:10.1016/j.aca.2026.345893 · Cited by 1
Riccardi, N., Martin, A., Pytel, D., Newman-Norlund, S. E., Carroll, S. L., Rorden, C., Fridriksson, J., & Bonilha, L. (2026) · npj Dementia · doi:10.1038/s44400-026-00115-6 · Cited by 1
Gaetani, L., Nardi, G., & Parnetti, L. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2700246 · Cited by 1
Plasma Phosphorylated Tau 217 in Participants at Risk for Chronic Traumatic Encephalopathy
Miner, A. E., Zetterberg, H., Blennow, K., Groh, J. R., Singh, A., Dieckhoff, K., Tripodis, Y., Adler, C. H., Balcer, L. J., Bernick, C. B., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.22966 · Cited by 1
Self-citationSpatiotemporal characterization of Alzheimer disease pathology in living human brain tissue
Aslanyan, A., Mukherjee, S., Moncur, E. M., Szadziewska, A., He, Y., Kac, P. R., Coyle, R. A., Camporesi, E., Sato, C., Ghoshal, N., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76494-4 · Cited by 1
Self-citationBiomarker in der Diagnostik kognitiver Störungen – Empfehlungen der Swiss Memory Clinics
Popp, J., Georgescu, D., Bürge, M., Mundwiler, E., Bernasconi, L., & Felbecker, A. (2022) · Praxis · doi:10.1024/1661-8157/a003913 · Cited by 1
Popp, J., Georgescu, D., Bürge, M., Mundwiler, E., Bernasconi, L., & Felbecker, A. (2022) · JMIG · doi:10.53738/revmed.2022.18.808.2400 · Cited by 1
Contribution of Global Amyloid-PET Imaging for Predicting Future Cognition in the MEMENTO Cohort
Ackley, S. F., Calmasini, C., Bouteloup, V., Hill‐Jarrett, T. G., Swinnerton, K. N., Chêne, G., Dufouil, C., Glymour, M. M., & for the MEMENTO Cohort Study Group and DPUK (2024) · Neurology · doi:10.1212/wnl.0000000000208054 · Cited by 1
Differenzialdiagnostik der Varianten der Alzheimerkrankheit
Gramespacher, H., Fink, G. R., & Onur, O. A. (2025) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-024-4158-6 · Cited by 1
Scotton, W. J., Shand, C., Todd, E. G., Bocchetta, M., Kobylecki, C., Cash, D. M., VandeVrede, L. A., Heuer, H. W., Quaegebeur, A., Young, A. L., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf066 · Cited by 3
Self-citationSato, K., Niimi, Y., Ihara, R., Iwata, A., Suzuki, K., Iwatsubo, T., & Initiative, A. D. N. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251350718 · Cited by 1
Fluid and Imaging Markers of Frontotemporal Lobar Degeneration
Prinse, F., Houwer, J. F. H. D., Dopper, E. G. P., & Seelaar, H. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_9 · Cited by 1
Fan, X., Ye, X., Xu, J., Mao, T., Zhang, R., Zhou, X., Yeung, C. C. K. A., Li, C., Chang, R. C., Lin, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202509376 · Cited by 2
A blood test for Alzheimer's disease: a step forward
Parnetti, L., Filippo, M. D., & Gaetani, L. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00254-4 · Cited by 1
Uncertainties in the PET defined A‐/TNeocortical+ subtype
Mormino, E. C., & Insel, P. S. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12348 · Cited by 1
Tagai, K., Tatebe, H., Matsuura, S., Zhang, H., Kokubo, N., Matsuoka, K., Endo, H., Oyama, A., Hirata, K., Shinotoh, H., et al. (2023) · medRxiv · doi:10.1101/2023.09.15.23295595 · Cited by 1
The Diagnostic Value of Blood Mir-132-3p Level in Patients with Alzheimer's DiseasePreprint
Zhang, H., Fu, X., Ren, X., Qi, Y., Song, X., Zhu, N., Yang, M., Dong, Y., Li, M., Tian, Y., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4449291/v1 · Cited by 1
Yan, K., He, S., Jia, X., Li, H., Liu, D., & Chen, J. (2024) · medRxiv · doi:10.1101/2024.08.15.24312085 · Cited by 1
Recasens, B. B., Ortiz‐Romero, P., Lugo-Hernández, F., Vidal-Notari, S., Diego‐Osaba, M. D., Blasco‐Forniés, H., Jiménez‐Moyano, E., Trujillano, M. L., Torres‐Torronteras, J., del Campo, M., et al. (2026) · medRxiv · doi:10.64898/2026.07.03.26356752 · Cited by 1
Baumel, J., Lutz, M., Ding, C., Capal, J., Ritter, D., Krueger, D., Salter, A., Werner, K., & Liu, A. J. (2026) · medRxiv · doi:10.64898/2026.09.09.26362677
Saunders, T. S., Heslegrave, A., King, D., Harris, S. E., Ritchie, C. W., Terrera, G. M., Deary, I. J., Cox, S. R., Zetterberg, H., & Spires‐Jones, T. L. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.24.469836
Self-citation16.MRCTにて海馬の萎縮が認められた恐怖性障害の1例(第15回日本心身医学会近畿地方会演題抄録)
上田, 文., 飯田, 順., 田原, 宏., & 井川, 玄. (1992) · 心身医学
New therapeutic opportunities for Alzheimer disease
Jang, J. (2022) · Journal of Geriatric Neurology · doi:10.53991/jgn.2021.00017
Reducing unnecessary tau-PET scans in a memory clinic setting via blood-based biomarker screeningPreprint
Cullen, N. C., Janelidze, S., Stomrud, E., Palmqvist, S., Braum, W., Zetterberg, H., Frisoni, G. B., Ashton, N. J., Blennow, K., Mattsson, N., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1818516/v1
Self-citationWeiner, M. W. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.94
BIOMARCADORES SANGUÍNEOS APLICADOS AO DIAGNÓSTICO PRECOCE DA DOENÇA DE ALZHEIMER
Gomes, E. M. D. M., da Silva, A. A., & Guerra, B. S. (2023) · Editora e-Publicar eBooks · doi:10.47402/ed.ep.c2023423115655
Beyond behavioral changes in semantic dementia: principal hurdles on the road to the clinic
Maia, M. V. R. F., Freitas, V. H. M., da Nóbrega, L. O., Coimbra, L. O., Lócio, A. M., Duarte, F. S., Ribeiro, R. M., Mororó, V. M., de Medeiros, S. D. P., de Menezes, A. R. B., et al. (2023) · Brazilian Journal of Clinical Medicine and Review · doi:10.52600/2965-0968.bjcmr.2023.1.3.49-57
Lateral flow assay for early diagnosis of neurodegenerative disorder
Kumawat, T. K., Parihar, A., Kumawat, V., Sharma, V. L., Pandit, A., Sharma, B., & Biyani, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95539-3.00013-2
Biomarker und Bildgebung in der Diagnose von Demenzen
Choe, C., & Jahn, H. (2023) · Neurologie up2date · doi:10.1055/a-1917-7368
A functional perspective on the conditional covariance comparison problem in dementia analysisPreprint
Guan, C., Gangopadhyay, A. K., & Initiative, T. A. D. N. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.19.572366
Axelsen, T. M., Høgh, P., Bihlet, A. R., Karsdal, M. A., Henriksen, K., Hasselbalch, S. G., & Simonsen, A. H. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.43
Suresh, K., Dahal, E., & Badano, A. G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.31.578167
Biomarker und Bildgebung in der Diagnose von Demenzen
Choe, C., & Jahn, H. (2024) · Geriatrie up2date · doi:10.1055/a-2250-9068
Major Neurocognitive Disorders Due to Frontotemporal Disease
Gopalakrishna, G., Sarangi, A., & Joshi, P. (2024) · Springer eBooks · doi:10.1007/978-3-031-55711-8_4
Cyclic 2.5D Perceptual Loss for Cross‐Modal 3D Medical Image Synthesis: T1w MRI to Tau PET
Moon, J., Kim, S., Chung, H., Jang, I., & Initiative, A. D. N. (2026) · Human Brain Mapping · doi:10.1002/hbm.70508 · Cited by 4
Novel blood-based proteomic signatures across multiple neurodegenerative diseasesPreprint
Durcan, R., Heslegrave, A., Swann, P., Goddard, J., Chouliaras, L., Murley, A. G., Savulich, G., Bevan-Jones, W. R., Swann, O., Ashton, N. J., et al. (2024) · medRxiv · doi:10.1101/2024.12.28.24319680
Self-citationWen, Y., Cannistra, M., Saccà, V., Ma, L., Liang, F., Xie, Z., & Kong, J. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149478
Metadata
- Authors
- Thijssen, E. H., La Joie, R., Strom, A., Fonseca, C., Iaccarino, L., Wolf, A., Spina, S., Allen, I. E., Cobigo, Y., Heuer, H., VandeVrede, L., Proctor, N. K., Lago, A. L., Baker, S., Sivasankaran, R., Kieloch, A., Kinhikar, A., Yu, L., Valentin, M.-A., Jeromin, A., Zetterberg, H., Hansson, O., Mattsson-Carlgren, N., Graham, D., Blennow, K., Kramer, J. H., Grinberg, L. T., Seeley, W. W., Rosen, H., Boeve, B. F., Miller, B. L., Teunissen, C. E., Rabinovici, G. D., Rojas, J. C., Dage, J. L., & Boxer, A. L.
- Affiliations
- University of California, San Francisco (US)
- Eli Lilly (United States) (US)
- Lawrence Berkeley National Laboratory (US)
- Quanterix (United States) (US)
- Sahlgrenska University Hospital (SE)
- Lund University (SE)
- Biogen (United States) (US)
- Mayo Clinic (US)
- Amsterdam Neuroscience (NL)
- Corresponding author
- Boxer, Adam L
- ORCID
- Thijssen, Elisabeth H
- Strom, Amelia
- Fonseca, Corrina
- Iaccarino, Leonardo
- Wolf, Amy
- Spina, Salvatore
- Allen, Isabel E
- Cobigo, Yann
- Heuer, Hilary
- VandeVrede, Lawren
- Proctor, Nicholas K
- Lago, Argentina Lario
- Baker, Suzanne
- Sivasankaran, Rajeev
- Kinhikar, Arvind
- Yu, Lili
- Zetterberg, Henrik
- Hansson, Oskar
- Graham, Danielle
- Blennow, Kaj
- Kramer, Joel H
- Grinberg, Lea T
- Seeley, William W
- Rosen, Howard
- Boeve, Bradley F
- Miller, Bruce L
- Teunissen, Charlotte E
- Rabinovici, Gil D
- Rojas, Julio C
- Dage, Jeffrey L
- Boxer, Adam L
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 20
- Issue
- 9
- Pages
- 739-752
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC8711249
- OpenAlex
- W3194829575
- Cited by
- 607
- References
- 40
- Citations by year
- 2026: 127 · 2025: 161 · 2024: 119 · 2023: 101 · 2022: 87 · 2021: 11
- FWCI
- 57.94
- Type
- journal article
- Language
- en
- Update notices
- erratum (2021-10-01)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Alzheimer's Association (AARF-16\u2013443577, 443577)
- National Center for Advancing Translational Sciences (LEFFTDS U01 AG045390)
- National Institute of Neurological Disorders and Stroke (U54NS092089)
- National Institute on Aging
- American College of Radiology
- Association for Frontotemporal Degeneration
- Rainwater Charitable Foundation
- NIH (R01 AG045611, U24AG21886, K24AG053435, R01AG038791, P50AG016574, K99AG065501, U19AG063911, P50AG023501, P01AG019724)
- Vetenskapsrådet (2018\u201302532, 02532)
- Little Family Foundation
- European Research Council (681712)
- Michael J Fox Foundation for Parkinson's Research
- Alzheimer's Drug Discovery Foundation (201809\u20132016862, 2016862, 201809)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- Alzheimer's disease, frontotemporal lobar degeneration, plasma biomarkers, diagnostic accuracy, mild cognitive impairment, tau PET, amyloid PET, primary progressive aphasia, corticobasal syndrome, progressive supranuclear palsy, behavioral variant frontotemporal dementia, posterior cortical atrophy, logopenic variant primary progressive aphasia, semantic dementia, electrochemiluminescence assay
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Phosphorylation, Predictive Value of Tests, Retrospective Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography, Frontotemporal Lobar Degeneration, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
